HRP20230177T1 - Antigeni citomegalovirusa i njihove uporabe - Google Patents
Antigeni citomegalovirusa i njihove uporabe Download PDFInfo
- Publication number
- HRP20230177T1 HRP20230177T1 HRP20230177TT HRP20230177T HRP20230177T1 HR P20230177 T1 HRP20230177 T1 HR P20230177T1 HR P20230177T T HRP20230177T T HR P20230177TT HR P20230177 T HRP20230177 T HR P20230177T HR P20230177 T1 HRP20230177 T1 HR P20230177T1
- Authority
- HR
- Croatia
- Prior art keywords
- fragment
- protein
- pentamer
- complex
- mutation
- Prior art date
Links
- 241000701022 Cytomegalovirus Species 0.000 title claims 5
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 21
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 7
- 102220510722 Dual specificity tyrosine-phosphorylation-regulated kinase 2_S98G_mutation Human genes 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 102220427461 c.289A>G Human genes 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 108700010903 cytomegalovirus proteins Proteins 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 102200012486 rs111033669 Human genes 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1. Rekombinantni gL protein citomegalovirusa ili (i) njegov gH/gL dimerni fragment koji stvara kompleks, (ii) njegov gH/gL/gO trimerni fragment koji stvara kompleks ili (iii) njegov gH/gL/pUL128/pUL130/pUL131 pentamerni fragment koji stvara kompleks, naznačen time što navedeni gL protein ili fragment sadrži mutaciju na ostacima mjesta prepoznavanja proteaze 91-102 numeriranih prema SEQ ID NO: 1, pri čemu navedena mutacija smanjuje cijepanje proteaze na navedenom mjestu prepoznavanja, u usporedbi s kontrolom, gdje je navedena mutacija odabrana između:
a) dodavanja F, Q, FQ ili QF između ostataka N97 i S98;
b) brisanja ostatka odabranog iz skupine koju čine: A95, A96, N97, i njihova kombinacija;
c) supstitucije A96 s ne-polarnim ostatkom ili s ostatkom koji sadrži veliki bočni lanac;
d) supstitucije A95 s R, L, E ili N;
e) supstitucije N97 s polarnim ostatkom ili ne-polarnim ostatkom;
f) supstitucije S98 s aminokiselinskim ostatkom s malim bočnim lancem;
g) zamjene V99 s I;
h) zamjene L100 s F ili V;
i) zamjene L101 s V ili I;
ili njihovu kombinaciju.
2. gL protein, ili fragment, prema zahtjevu 1, naznačen time što je supstitucija A96 u c) s I, L, V ili S.
3. gL protein, ili fragment, prema bilo kojem od zahtjeva 1-2, naznačen time što je supstitucija N97 u e) s polarnim ostatkom koji sadrži mali bočni lanac.
4. gL protein, ili fragment, prema bilo kojem od zahtjeva 1-2, naznačen time što je supstitucija N97 u e) s polarnim ostatkom koji sadrži veliki bočni lanac.
5. gL protein, ili fragment, prema bilo kojem od zahtjeva 1-4, naznačen time što je supstitucija S98 u f) s G, T, V, ili I.
6. gL protein, ili fragment, prema zahtjevu 1, naznačen time što je navedena mutacija trostruka mutacija A96L/N97S/S98G.
7. gL protein, ili fragment, prema zahtjevu 1, naznačen time što je navedena mutacija trostruka mutacija A96I/N97D/S98G.
8. Proteinski kompleks citomegalovirusa sadrži rekombinantni gL protein, ili fragment, prema bilo kojem od zahtjeva 1-7.
9. Kompleks prema patentnom zahtjevu 8, naznačen time što navedeni kompleks je pentamerni kompleks koji nadalje sadrži: gH ili njegov fragment koji stvara pentamer, pUL128 ili njegov fragment koji stvara pentamer, pUL130 ili njegov fragment koji stvara pentamer, i pUL131 ili njegov fragment koji stvara pentamer.
10. Izolirana nukleinska kiselina koja sadrži polinukleotidnu sekvencu koja kodira rekombinantni gL protein citomegalovirusa, ili fragment, prema bilo kojem od zahtjeva 1-7.
11. Stanica domaćina, poželjno stanica domaćina sisavca, koja sadrži nukleinsku kiselinu prema zahtjevu 10.
12. Stanica domaćina prema zahtjevu 11, naznačena time što navedena stanica domaćin nadalje sadrži jednu ili više polinukleotidnih sekvenci koje kodiraju gH ili njegov fragment koji stvara pentamer, pUL128 ili njegov fragment koji stvara pentamer, pUL130 ili njegov fragment koji stvara pentamer, i pUL131 ili njegov fragment koji stvara pentamer.
13. Imunogeni pripravak koji sadrži rekombinantni gL protein citomegalovirusa, ili fragment, prema bilo kojem od zahtjeva 1-7, ili kompleks prema bilo kojem od zahtjeva 8-9, i izborno sadrži pomoćno sredstvo.
14. Imunogeni pripravak prema zahtjevu 13 za uporabu u induciranju imunološkog odgovora protiv citomegalovirusa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152221.6A EP3048114A1 (en) | 2015-01-22 | 2015-01-22 | Cytomegalovirus antigens and uses thereof |
| PCT/IB2016/050335 WO2016116904A1 (en) | 2015-01-22 | 2016-01-22 | Cytomegalovirus antigens and uses thereof |
| EP16702210.2A EP3247722B1 (en) | 2015-01-22 | 2016-01-22 | Cytomegalovirus antigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230177T1 true HRP20230177T1 (hr) | 2023-04-14 |
Family
ID=52434568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230177TT HRP20230177T1 (hr) | 2015-01-22 | 2016-01-22 | Antigeni citomegalovirusa i njihove uporabe |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10167321B2 (hr) |
| EP (3) | EP3048114A1 (hr) |
| JP (1) | JP6717836B2 (hr) |
| KR (1) | KR20170100039A (hr) |
| CN (1) | CN107531761B (hr) |
| AU (2) | AU2016210548B2 (hr) |
| BE (1) | BE1023087B1 (hr) |
| BR (1) | BR112017015567A2 (hr) |
| CA (1) | CA2974041C (hr) |
| DK (1) | DK3247722T3 (hr) |
| EA (1) | EA038250B1 (hr) |
| ES (1) | ES2937959T3 (hr) |
| FI (1) | FI3247722T3 (hr) |
| HR (1) | HRP20230177T1 (hr) |
| HU (1) | HUE061175T2 (hr) |
| IL (1) | IL253366B (hr) |
| LT (1) | LT3247722T (hr) |
| MX (1) | MX2017009538A (hr) |
| PL (1) | PL3247722T3 (hr) |
| PT (1) | PT3247722T (hr) |
| SG (1) | SG11201705740UA (hr) |
| SI (1) | SI3247722T1 (hr) |
| WO (1) | WO2016116904A1 (hr) |
| ZA (1) | ZA201704912B (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3333265T3 (da) * | 2010-05-14 | 2020-04-27 | Univ Oregon Health & Science | Rekombinante hcmv- og rhcmv-vektorer der koder for et heterologt antigen isoleret fra hepatitis b-virus og anvendelser deraf |
| WO2012170765A2 (en) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR101996427B1 (ko) | 2014-07-16 | 2019-07-04 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| KR20170136512A (ko) | 2015-02-10 | 2017-12-11 | 오레곤 헬스 앤드 사이언스 유니버시티 | 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물 |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| JP7133468B2 (ja) | 2015-11-20 | 2022-09-08 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
| EP3423091A4 (en) | 2016-03-03 | 2019-10-30 | Duke University | COMPOSITIONS AND METHODS OF INDUCING HIV-1 ANTIBODIES |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| WO2018067580A1 (en) | 2016-10-03 | 2018-04-12 | Duke University | Methods to identify immunogens by targeting improbable mutations |
| EP3529363A4 (en) | 2016-10-18 | 2020-05-06 | Oregon Health & Science University | CYTOMEGALOVIRUS VECTORS, CALLING OUT T-CELLS, RESTRICTED BY A LARGE HISTOCOMPATIBILITY COMPLEX E-MOLECULE |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| US20230248820A1 (en) | 2017-04-19 | 2023-08-10 | Glaxosmithkline Biologicals, S.A. | Modified cytomegalovirus proteins and stabilized complexes |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| WO2019070730A1 (en) | 2017-10-02 | 2019-04-11 | Duke University | MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES |
| WO2019169120A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
| WO2020079586A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| CN109627330A (zh) * | 2018-12-18 | 2019-04-16 | 马鞍山史记动物健康管理有限公司 | 一种猪伪狂犬病毒高效价阳性血清制备方法 |
| WO2021014385A1 (en) | 2019-07-24 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| CA2045175C (en) | 1989-11-06 | 2003-03-18 | Arthur I. Skoultchi | Production of proteins using homologous recombination |
| WO2007146024A2 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| PE20141432A1 (es) * | 2008-07-16 | 2014-10-18 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
| SG178954A1 (en) | 2009-09-02 | 2012-04-27 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2716243T3 (es) | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
| RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| CN104853771A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 巨细胞病毒蛋白的复合物 |
| ES2608637T3 (es) * | 2012-10-30 | 2017-04-12 | Pfizer Inc. | Vacunas basadas en partículas recombinantes contra la infección por el citomegalovirus humano |
| CN106029692A (zh) | 2013-12-20 | 2016-10-12 | 诺华股份有限公司 | 用于重组表达感兴趣产物的新型真核细胞和方法 |
| BR112016013420A2 (pt) | 2013-12-20 | 2017-09-26 | Novartis Ag | células eucarióticas e métodos para expressar recombinantemente um produto de interesse |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
-
2015
- 2015-01-22 EP EP15152221.6A patent/EP3048114A1/en not_active Withdrawn
-
2016
- 2016-01-22 HU HUE16702210A patent/HUE061175T2/hu unknown
- 2016-01-22 FI FIEP16702210.2T patent/FI3247722T3/fi active
- 2016-01-22 BE BE2016/5050A patent/BE1023087B1/fr not_active IP Right Cessation
- 2016-01-22 US US15/544,730 patent/US10167321B2/en active Active
- 2016-01-22 CN CN201680017610.XA patent/CN107531761B/zh active Active
- 2016-01-22 SG SG11201705740UA patent/SG11201705740UA/en unknown
- 2016-01-22 CA CA2974041A patent/CA2974041C/en active Active
- 2016-01-22 PT PT167022102T patent/PT3247722T/pt unknown
- 2016-01-22 PL PL16702210.2T patent/PL3247722T3/pl unknown
- 2016-01-22 HR HRP20230177TT patent/HRP20230177T1/hr unknown
- 2016-01-22 KR KR1020177023123A patent/KR20170100039A/ko not_active Application Discontinuation
- 2016-01-22 MX MX2017009538A patent/MX2017009538A/es unknown
- 2016-01-22 DK DK16702210.2T patent/DK3247722T3/da active
- 2016-01-22 EP EP16702210.2A patent/EP3247722B1/en active Active
- 2016-01-22 EA EA201791562A patent/EA038250B1/ru unknown
- 2016-01-22 WO PCT/IB2016/050335 patent/WO2016116904A1/en active Application Filing
- 2016-01-22 ES ES16702210T patent/ES2937959T3/es active Active
- 2016-01-22 AU AU2016210548A patent/AU2016210548B2/en active Active
- 2016-01-22 JP JP2017538387A patent/JP6717836B2/ja active Active
- 2016-01-22 LT LTEPPCT/IB2016/050335T patent/LT3247722T/lt unknown
- 2016-01-22 EP EP22203406.8A patent/EP4180056A1/en active Pending
- 2016-01-22 SI SI201631665T patent/SI3247722T1/sl unknown
- 2016-01-22 BR BR112017015567A patent/BR112017015567A2/pt active Search and Examination
-
2017
- 2017-07-09 IL IL253366A patent/IL253366B/en unknown
- 2017-07-19 ZA ZA2017/04912A patent/ZA201704912B/en unknown
-
2018
- 2018-09-10 AU AU2018226521A patent/AU2018226521B2/en active Active
- 2018-11-15 US US16/192,347 patent/US20190276498A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230177T1 (hr) | Antigeni citomegalovirusa i njihove uporabe | |
| JP2018504117A5 (hr) | ||
| NZ754510A (en) | Virulence attenuated bacteria based protein delivery | |
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| BR112017027448A2 (pt) | vacina contra rsv | |
| JP2009540801A5 (hr) | ||
| NZ753307A (en) | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof | |
| JP2014504851A5 (hr) | ||
| JP2017513502A5 (hr) | ||
| HRP20200418T1 (hr) | Terapeutska uporaba koštanih morfogenetičkih proteina | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| MX2021004397A (es) | Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos. | |
| JP2018531624A5 (hr) | ||
| PE20180509A1 (es) | Composiciones y metodos para tratar la enfermedad celiaca | |
| Jiang et al. | Immune responses of channel catfish following the stimulation of three recombinant flagellins of Yersinia ruckeri in vitro and in vivo | |
| MX2019003158A (es) | Vectores de adenovirus canino. | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| WO2006116763A3 (en) | Lawsonia intracellularis immunological proteins | |
| MX2017015927A (es) | Fragmentos mutantes de proteina ras. | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| NZ760008A (en) | Uti fusion proteins | |
| JP2019534709A5 (hr) | ||
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| MX2019011259A (es) | Adyuvante mejorado de vacuna de li. |